MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants
Since the coronavirus disease outbreak in 2019, several antibody therapeutics have been developed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Antibody therapeutics are effective in neutralizing the virus and reducing hospitalization in patients with mild and mod...
Guardado en:
Autores principales: | Sua Lee, Shina Jang, Jihoon Kang, Soo Bin Park, Young Woo Han, Hyemi Nam, Munkyung Kim, Jeewon Lee, Ki Joon Cho, Jeonghun Kim, Miyoung Oh, Jihye Ryu, Jong Hyeon Seok, Yunhwa Kim, Jee-Boong Lee, Man-Seong Park, Yong-Sung Kim, Hosun Park, Dong-Sik Kim |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7e740e1bfe9248e3844839c81b27bd6d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Analysis of COVID-19 outbreak origin in China in 2019 using differentiation method for unusual epidemiological events
por: Radosavljevic Vladan
Publicado: (2021) -
Acta N°1141
por: Banco Central de Chile
Publicado: (2021) -
Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease
por: Ji Yeon Lee, et al.
Publicado: (2021) -
Habitat utilization of two muroid species in relation to population outbreaks in southern temperate forests of Chile
por: GONZALEZ,LUZ A, et al.
Publicado: (2000) -
Delays in the diagnosis and treatment of tuberculosis during the COVID-19 outbreak in the Republic of Korea in 2020
por: Jiyeon Yang, et al.
Publicado: (2021)